Introduction
Contact allergies are a growing problem in the world [1] . 20-25% of the European population is sensitive to at least one contact allergen [2] . These allergens are lowmolecular-weight compounds that can penetrate skin, bind to epidermal proteins, and induce sensitization. Allergic contact dermatitis (ACD) is a T cell-mediated inflammatory skin disease classified as a delayed-type hypersensitivity reaction [3] .
The diagnosis of ACD is based on clinical history and patch testing. The patch test determines whether a specific substance causes allergic inflammation of a patient's skin. The positive patch test indicates contact sensitization of present or past relevance. One of the disadvantages of this method is the invasiveness of the test. Moreover, sometimes the test gives false-positive and falsenegative results, which can be correctly interpreted only by experienced allergists [4] .
There have been several attempts to develop noninvasive tests to replace the patch test [5] [6] [7] . For example, a lymphocyte transformation test was developed for patients in whom the patch caused exacerbation of symptoms [8] . However, the lymphocyte transformation test can only be used in the diagnosis of nickel allergies on account of the low specificity and sensitivity of the test for other metals [9] . Enzymatic assays have also shown promise as diagnostic tools for ACD [10] [11] [12] . In particular, an ELISpot assay, which can detect serum levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ, was developed for ACD diagnostics [13] .
Here, we used rapid and sensitive immunoassays to simultaneously monitor the levels of 102 human cytokines, chemokines, and growth factors in the serum of 16 ACD patients and 16 control individuals. We showed that serum levels of 11 proteins [adiponectin, chemokine (C-C motif) ligand 5 (CCL5), C-reactive protein (CRP), chitinase 3-like 1 (CHI3L1), complement factor D (CFD), endoglin, lipocalin-2, osteopontin, retinol-binding protein 4 (RBP4), platelet factor 4 (PF4), and trefoil factor 3 (TFF3)] differed between ACD patients and healthy controls. Moreover, serum levels of 4 proteins [CCL5, TFF3, soluble intercellular adhesion molecule-1 (sICAM-1), and platelet-derived growth factor (PDGF)-AB/BB] differed in ACD patients during acute and remission phases of the disease. Our results suggest that immunoassaybased monitoring of several serum proteins might be further exploited in diagnosis and treatment of ACD.
Materials and Methods
This study was approved by the Lithuanian Bioethics Committee (ethical approval No. 158200-14-714-231), and written consent was obtained from each participant. We recruited 16 individuals (15 females and 1 male; 21-54 years of age, mean 33.1 ± 10.6) with preliminary diagnosis of acute-phase ACD by the Centre for Diagnosis and Treatment of Allergic Diseases, Vilnius, Lithuania, in January 2014. Serum samples were collected from these individuals, and then collected again during the remission phase of ACD.
The control group consisted of 16 volunteers without a previous history of ACD (15 females and 1 male; age 21-35 years, mean 27.6 ± 7.6). Volunteers did not have any chronic inflammatory or metabolic diseases. We collected serum samples from the control group twice, with a 1-month interval between sampling.
The patch tests were performed in the case and control groups using European standards (S-1000; Chemotechnique Diagnostics, Sweden). Tests for other allergens were performed according to clinical needs. Patch tests were performed on the upper back of participants. Palpable erythema, indicating a positive reaction to the patch test, was evaluated after 1-3 days. The severity of patch test reactions were graded from no reaction (-) to 3+ [14] . Importantly, patients did not use local and/or systemic corticosteroids for at least 1 month, and treatment with antihistamines was stopped for 4-6 days before patch testing.
The relative levels of 102 cytokines, chemokines, and growth factors were determined using the Proteome Profiler Human XL Cytokine Array Kit (R&D Systems Inc., USA) according to the manufacturer's instructions. Importantly, this immunoassay was chosen because it includes several biomarkers (e.g. IL-4, IL-5, IL-10, IL-13, adiponectin, CRP, CHI3L1, CCL5, lipocalin-2, and osteopontin), which were previously associated with ACD [10] [11] [12] [15] [16] [17] [18] [19] [20] .
GraphPad Prism software was used for statistical analysis. The differences in protein levels between paired groups were calculated using a nonparametric Wilcoxon signed rank test. The differences between nonpaired groups were analyzed using a Mann-Whitney U test.
Results
We recruited 16 individuals with a preliminary diagnosis of ACD during the acute phase of the disease. After approximately 1 month from onset of symptoms (remission phase), we performed patch tests which confirmed preliminary ACD diagnosis ( table 1 ) . We also recruited 16 volunteers without a previous medical history of ACD. We performed a patch test for this group to confirm the absence of ACD. We collected paired serum samples from ACD patients (during acute and remission phases) and from patch test-negative volunteers (1-month interval).
We profiled 102 cytokines, chemokines, and growth factors in 4 groups of serum samples using immunoassay. We observed significant differences between the serum levels of 11 proteins of ACD cases versus healthy controls, as well as variations between the serum levels of 4 proteins of ACD patients during acute and remission phases ( table 2 ). In particular, the serum levels of adiponectin, CCL5, CRP, CHI3L1, CFD, endoglin, lipocalin-2, osteopontin, RBP4, and PF4 were elevated, whereas the level of TFF3 was decreased, in ACD patients in comparison with healthy controls. Furthermore, the serum levels of CCL5 were increased (p ≤ 0.05), whereas the levels of TFF3, sICAM-1, and PDGF-AB/BB were decreased in remission, versus the acute phase of ACD (p ≤ 0.005, p ≤ 0.05, and p ≤ 0.05, respectively).
Discussion
Our pilot immunological analysis of 102 serum cytokines, chemokines, and growth factors identified significant differences in levels of adiponectin, CCL5, CRP, CHI3L1, CFD, endoglin, lipocalin-2, osteopontin, RBP4, PF4, and TFF3 between ACD cases and healthy controls. Importantly, adiponectin, CRP, CHI3L1, CCL5, lipocalin-2, and osteopontin were shown to act as proinflammatory proteins, whereas endoglin and PF4 were shown to act as anti-inflammatory proteins in ACD [15] [16] [17] [18] [19] [20] . Our results suggest that the differences in serum levels of these proteins between ACD patients and healthy individuals might be exploited in diagnosis of ACD. Moreover, immunological diagnosis of ACD might be done without restriction to contact allergens, and might be appropriate for those cases where application of the patch test is problematic. Our analysis also revealed variations in the levels of CCL5, TFF3, sICAM-1, and PDGF-AB/BB between the acute and remission phases in ACD patients. The roles of sICAM-1, PDGF-AB/BB, and TFF3 remain unclear in ACD; however, these proteins were shown to play immunomodulatory functions in other diseases [21] [22] [23] . Thus, the levels of CCL5, TFF3, sICAM-1, and PDGF-AB/BB might be exploited in monitoring the progression of ACD, and perhaps evaluating the effectiveness of treatment. However, further replication studies with a larger number of subjects are necessary to validate our results.
